Intercept Pharmaceuticals’ $172.5 Million Follow-on Offering

Orrick represented Credit Suisse and Jefferies as underwriters for a follow-on public offering of 2,695,313 shares of common stock by Intercept Pharmaceuticals, Inc. (“Intercept”), including shares…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now